Immunic, Inc. Appoints Patrick Walsh News Director

Immunic, Inc. Appoints Patrick Walsh  News Director

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s three development programs and the targeted diseases; the potential for Immunic’s development programs to safely and effectively target diseases; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; expectations regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 26, 2021, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release. About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: www.imux.com. Contact Information

Mr. Walsh holds both an M.S. in molecular, cellular and developmental biology and an MBA from the University of Michigan and a B.A. in biology and economics from Colby College. Mr. Walsh joins Immunic from Akebia Therapeutics, Inc., where he served as Vice President of News Development and completed an array of strategic transactions, including multiple partnerships, in-licenses, non-dilutive financings, and a merger. Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development. Earlier in his career, he was a consultant to life science companies with Capgemini SE and was on the healthcare investment banking team at Leerink Partners (now SVB Leerink).

“I am thrilled to be part of Immunic’s very talented team,” said Mr. Walsh. “I hope to leverage my experience to advance the development and commercial potential of the company’s extraordinary wealth of assets, including three clinical-stage candidates and several promising preclinical compounds, to reinforce our mission to bring innovative, safe and easy-to-use treatment options to patients in need.” “Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies. He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. “I am pleased to welcome Patrick to our executive team and look forward to leveraging his experience as we work to realize the full potential of our clinical programs.”

Immunic, Inc. Logo (PRNewsfoto/Immunic, Inc.) View original content to download multimedia: US Media ContactKOGS CommunicationEdna Kaplan+1 781 639 1910kaplan@kogspr.com

US IR ContactRx Communications GroupPaula Schwartz+1 917 322 2216immunic@rxir.com Immunic, Inc.Jessica BreuHead of Investor Relations and Communications+49 89 2080 477 09jessica.breu@imux.com

The News Highlights

  • Immunic, Inc. Appoints Patrick Walsh News Director
  • Check the latest News news updates and information about business, finance and more.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
The crackdown on ‘chemicals forever’ could hit Connecticut manufacturers
The crackdown on ‘chemicals forever’ could hit Connecticut manufacturers
State lawmakers earlier this year passed some of the toughest regulations in the nation regarding PFAS, banning their use in most firefighting foams and food ...
For People Working From Home, Sony NB10 Neckband Speaker Is Good
For People Working From Home, Sony NB10 Neckband Speaker Is Good
And, at least in that scenario, the product is an interesting idea worth exploring. The gist of the Sony SRS-NB10 is a speaker that’s worn around your neck. ...
Report: Foreign aid lost in currency distortions in Syria
Report: Foreign aid lost in currency distortions in Syria
“Assad does not merely profit from the crisis he has created,” the report added. “He has created a system that rewards him more the worse things get.” ...
Microsoft is working on a ‘Wu-Tang Clan’ RPG, according to reports
Microsoft is working on a ‘Wu-Tang Clan’ RPG, according to reports
He went on to say that he wasn’t sure if he was talking about Wu-Tang, the martial art system, or Wu-Tang Clan, the prominent hip-hop group. Jez Corden, a ...
The Crypto Daily – Movers and Shakers – October 24, 2021
The Crypto Daily – Movers and Shakers – October 24, 2021
Across the rest of the majors, it was a bullish day on Saturday. The Rest of the Pack Chainlink rallied by 9.58% to lead the way, with Crypto.com Coin ...
PaDucky Derby Raises Money for Local Crisis Center |  News
PaDucky Derby Raises Money for Local Crisis Center | News
“I think if anything this community continues to show us that the sky really is the limit. So, if they’re not to their limit then we’re not either. We hope to ...
Instagram is testing a desktop posting feature
Austrian Chancellor Threatens Blockade for Unvaccinated
Schallenberg announced that if the number of COVID-19 patients in intensive care units reaches 500, or 25% of the country’s total ICU capacity, entry into ...
End of extra unemployment benefit and hiring companies |  The business
ASEAN leaders hold meeting with excluded Myanmar general
ASEAN’s unprecedented sanctioning of Myanmar strayed from its bedrock principles of non-interference in each other’s domestic affairs and deciding by ...
State seeks information on drinking water spending priorities
State seeks information on drinking water spending priorities
The funding helps municipalities, farmers and others create projects that reduce pollution washing into waterways, ranging from farmers planting cover crops ...
Croatians can now travel to the US for business and tourist purposes without visas
Croatians can now travel to the US for business and tourist purposes without visas
Back then, it was reported that Croatians would be allowed to travel without visas to the US for business or tourism purposes with only travel permission ...
Show next
Compsmag - Latest News from tech, business and health
Logo